REG-4basebio Plc: Director's Dealing

4BasebioAnnouncement

03/03/2025 16:45

3 March 2025

4basebio plc

(“4basebio” or the "Company")
 

Director’s Dealing

3 March 2025 – 4basebio PLC (AIM: 4BB), which develops and commercialises
the large-scale manufacture of synthetic DNA as well as nanoparticle delivery
solutions, announces that it was informed on 28 February 2025 by Dr. Amy
Walker, COO of the Company, that on the same day, she acquired ordinary shares
in the Company through the market, at a price of 1,120p as follows: 

 Name            Numberof Shares Acquired  Shareholding Prior to the Acquisition  Shareholding Following the Acquisition   Enlarged Shareholding as a Percentage of Issued Share Capital  
 Dr. Amy Walker  1,151                     42,865*                                44,016                                   0.28%                                                          

* Dr Walker’s shareholding includes 2,818 ordinary shares that had been
omitted in the announcement of 8 August 2024

The issued share capital of the Company comprises 15,477,395 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

Enquiries

 4basebio PLC Dr. Heikki Lanckriet                                                      +44 (0)1223 967 943  
 Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes  +44 (0)20 7213 0880  
 Joint Corporate Broker RBC Capital Markets Rupert Walford / Kathryn Deegan             +44 (0)20 7653 4000  
 Joint Corporate Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks      +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014                                                                                                                                              
 1   Details of the person discharging managerial responsibilities/person closely associated                                                                                                                                          
 a.  Name                                                         Amy Walker                                                                                                                                                          
 2   Reason for notification                                                                                                                                                                                                          
 a.  Position/Status                                              COO                                                                                                                                                                 
 b.  Initial notification/Amendment                               Initial Notification                                                                                                                                                
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                                                    
 a.  Name                                                         4basebio plc                                                                                                                                                        
 b.  LEI                                                          213800E2DX9EAIUNCB30                                                                                                                                                
 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted                                
 a.  Description of the financial instrument, type of instrument  Ordinary Shares                                                                                                                                                     
     			                                                                                                                                                                                                                              
     			Identification Code                                        ISIN: GB00BMCLYF79                                                                                                                                                 
 b.  Nature of the transaction                                    Acquisition of ordinary shares                                                                                                                                      
                                                                                                           Price(s) per share (p)                   Volume(s)                                                                         
     1,120p                                                                                                1,151                                                                                                                      
                                                                                                                                                        
 d.  Aggregated information * Volume                              * 1,151                                                                                                                                                             
     * Price                                                      * 1,120 pence per share                                                                                                                                             
 e.  Date of the transaction                                      28/02/2025                                                                                                                                                          
 f.  Place of the transaction                                     London Stock Exchange, AIM                                                                                                                                          



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved